ACC501 MOD2 SLP2 Part 2-A Revised Income Statement

ACC501 MOD2 SLP2 Part 2-A Revised Income Statement -...

Info iconThis preview shows pages 1–3. Sign up to view the full content.

View Full Document Right Arrow Icon
Running head: A REVISED INCOME STATEMENT 1 A Revised Income Statement – Breakeven Analysis ________________________ TUI University 3/26/12
Background image of page 1

Info iconThis preview has intentionally blurred sections. Sign up to view the full version.

View Full DocumentRight Arrow Icon
A REVISED INCOME STATEMENT 2 A Revised Income Statement – Breakeven Analysis Breakeven Analysis – Part II Johnson & Johnson (JNJ) was chosen for the breakeven analysis and is a manufacturer, researcher and developer, and seller of many healthcare products. JNJ was incorporated in the State of New Jersey in 1887 and currently has more than 250 operating subsidiaries and 114,000 employees worldwide (Hoovers, 2011). The company is categorized into three segments that include consumer, pharmaceutical and medical devices and diagnostics (JNJ, 1997-2011). For the purposes of this analysis, LISTERINE® was selected as the company was acquired by JNJ as a result of Pfizer’s consumer healthcare division in late December 2006 (Pitman, June 27, 2006). Following are some of the assumptions made in computing the breakeven analysis for LISTERINE®: Average selling price of LISTERINE® is assumed to be approximately $5.50 per
Background image of page 2
Image of page 3
This is the end of the preview. Sign up to access the rest of the document.

Page1 / 5

ACC501 MOD2 SLP2 Part 2-A Revised Income Statement -...

This preview shows document pages 1 - 3. Sign up to view the full document.

View Full Document Right Arrow Icon
Ask a homework question - tutors are online